News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
Drug-resistant TB
Tuberculosis: Europe’s Ticking Timebomb

On World Tuberculosis Day the TB Europe Coalition called on the European Commission to substantially increase funding to fight tuberculosis in Europe. Tuberculosis causes not only illness and death, according to estimates, it costs EU Member States €15 million every week and €750 million every year.

Published
20 March 2013
From
TB Europe Coalition
Drug-resistant TB
World Health Organization and Global Fund cite tuberculosis threat

WHO and the Global Fund to Fight AIDS, TB and Malaria said today that strains of tuberculosis with resistance to multiple drugs could spread widely and highlight an annual need of at least US$ 1.6 billion in international funding for treatment and prevention of the disease.

Published
18 March 2013
From
World Health Organization
Drug-resistant TB
Global Drug Facility achieves price reduction for drug-resistant TB treatments

The Stop TB Partnership’s Global Drug Facility has reduced the price of several second-line drugs it supplies for the treatment of multidrug resistant tuberculosis (MDR-TB) by up to 26% compared to 2011 prices, resulting in a decrease in the overall cost of treatment.

Published
18 March 2013
From
Stop TB Partnership
Tuberculosis and HIV
Report of the HIV/TB Research meeting held in conjunction with the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)

The World Health Organization and the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) convened their 7th CROI-affiliated HIV/TB research meeting on behalf of the TB/HIV Working Group of the Stop TB Partnership in Atlanta, Georgia USA on 3 March, 2013. The meeting discussed critical knowledge and research gaps on TB prevention among children and adults and drug interactions between new TB drugs and ART.

Published
14 March 2013
From
Stop TB Partnership
Drug-resistant TB
An Activist’s Guide to Bedaquiline (Sirturo)

Bedaquiline (also known by its trade name, Sirturo, or as TMC207) is the first new drug from a new drug class to treat TB to be approved by the United States Food and Drug Administration (FDA) in over 40 years. This guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward. .

Published
12 March 2013
From
Treatment Action Group
Drug-resistant TB
Ukraine: Curbing the MDR-TB Epidemic in Prisons

Once considered a disease on the decline, tuberculosis (TB) has seen a resurgence in Ukraine and several other post-Soviet countries that endured social and economic tumult after the collapse of the Soviet Union.

Published
10 March 2013
From
Doctors Without Borders
TB treatment
Dosing of key TB drug rifampicin could go higher

Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug

Published
07 March 2013
By
Keith Alcorn
TB treatment
Once-weekly continuation phase TB treatment equals standard of care

A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month continuation phase, Dr Amina Jindani of St

Published
07 March 2013
By
Keith Alcorn
Drug-resistant TB
Dangerous TB Patient Nabbed On US Border

In medical isolation in South Texas, 100 miles or so from Mexico's border, is a man who embodies one of U.S. health officials' greatest worries: He is the first person to cross and be held in detention while infected with one of the most severe types of drug-resistant tuberculosis known today.

Published
03 March 2013
From
Wall Street Journal
Health monitoring in resource-limited settings
Alere to Develop Simple, Affordable Point-of-Care Nucleic Acid Test for Tuberculosis & Expand Manufacturing for POC HIV Viral Load Platform

Alere Inc. announced that it has been awarded a grant of up to $21.6 million and debt financing of up to $20.6 million from the Bill & Melinda Gates Foundation to support development of a point-of-care nucleic acid test for tuberculosis and to expand production facilities for this test and for a point-of-care viral load test.

Published
02 March 2013
From
Alere
← Prev12345...69Next →

Filter by country